Sunshine Biopharma (NASDAQ:SBFM) is a clinical-stage biotechnology company focused on the development of novel, small molecule therapies for the treatment of various forms of cancer. The company’s research and development efforts center on the synthesis and preclinical evaluation of synthetic cannabinoid compounds and related analogs designed to target tumor cell proliferation and metastasis. By leveraging proprietary chemistry platforms, Sunshine Biopharma aims to advance its lead candidates through preclinical toxicology studies and toward Investigational New Drug (IND) applications with regulatory authorities.
Beyond its oncology pipeline, Sunshine Biopharma has established a contract research and manufacturing services division. This segment provides custom synthesis, analytical testing and scale‐up production services to pharmaceutical and biotech clients. Operating out of a manufacturing facility in Montreal, Canada, the company offers Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) capabilities, enabling third‐party partners to accelerate development of both small molecule and cannabinoid‐derived APIs.
Founded in 2013, Sunshine Biopharma has built a multidisciplinary leadership team with expertise in medicinal chemistry, pharmacology and regulatory affairs. Chief Executive Officer and Chief Scientific Officer Dr. Ron F. Krabill brings over 25 years of drug discovery experience, while President and Chief Operating Officer Mr. Brent Livingston oversees corporate strategy and business development. The company’s board includes members with extensive backgrounds in oncology research, clinical trial design and intellectual property management.
Sunshine Biopharma’s operations extend primarily across North America, with research collaborations and contract manufacturing partnerships in the United States and Canada. By maintaining an integrated model that combines in‐house drug discovery with client‐driven services, the company seeks to de‐risk its proprietary pipeline while generating revenue through fee‐for‐service engagements. This dual approach positions Sunshine Biopharma to advance its oncology programs toward clinical milestones and support external collaborators in meeting their development objectives.
AI Generated. May Contain Errors.
